Cure My Disease

Don't miss your cure!

 Log in / Sign up

Melanoma survivors: new study tracks immunotherapy side effects

NCT ID NCT04990726

Ongoing Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 126 melanoma survivors who are receiving immunotherapy after surgery. Researchers will track side effects and quality of life for up to 24 months. They will also collect blood samples to look for markers that might predict who gets side effects. The goal is to better understand and manage these side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors better predict and manage immunotherapy side effects in melanoma survivors, improving quality of life.

What could go wrong

This is an observational study, not a treatment trial. It may not find clear links between side effects and blood markers, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 MELANOMA STAGE II MELANOMA STAGE IV PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIID CUTANEOUS MELANOMA AJCC V8

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States